ACAD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, ACADIA Pharmaceuticals Inc. (ACAD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and potential for upside make it a suitable investment despite the lack of immediate trading signals.
The stock's MACD is below 0 and negatively contracting, indicating a lack of strong upward momentum. RSI is neutral at 63.769, and moving averages are converging, suggesting no clear trend. The price is near resistance level R1 (24.251), with potential upside to R2 (24.997).
Strong financial performance in Q3 2025 with revenue up 11.27% YoY, net income up 119.07% YoY, and EPS up 110.00% YoY.
Analysts maintain positive sentiment with multiple Buy ratings and price targets ranging from $31 to $
Stock trend analysis indicates a 70% chance of a 7.04% increase in the next month.
The MACD indicator is below 0, showing weak momentum.
Gross margin dropped slightly by -0.26% YoY.
Negative CHMP trend vote on Daybue reduces the likelihood of a long-term revenue source, though re-examination is pending.
In Q3 2025, ACADIA Pharmaceuticals saw revenue increase by 11.27% YoY to $278.63M, net income increase by 119.07% YoY to $71.78M, and EPS increase by 110.00% YoY to $0.42. However, gross margin dropped slightly to 92.23%, down -0.26% YoY.
Analysts are generally positive on ACAD, with multiple Buy ratings and price targets ranging from $31 to $40. RBC Capital acknowledges risks with the CHMP vote but sees potential for reversal. Canaccord and UBS highlight the undervalued nature of the stock and its underappreciated pipeline.
